Objective. Mitochondrial DNA (mtDNA) loss in peripheral blood mononuclear cells (PBMCs) has been found in both nucleoside reverse-transcriptase inhibitor (NRTI)-exposed and antiretroviral therapy (ART)-naive patients with human immunodeficiency virus (HIV) infection. Persistent immune activation might play a role in this phenomenon in HIV-infected, ART-naive patients. PBMC subsets with differential growth kinetics were therefore purified to study this similarity.
Combination antiretroviral therapy (ART) has reduced morbidity and mortality among HIV-infected patients over the last decade [1] and, therefore, has caused a shift in focus toward concern for long-term adverse effects.
Mitochondrial toxicity appears to be an underlying mechanism for several long-term adverse effects that are related to treatment with nucleoside reverse-transcriptase inhibitors (NRTIs) [2] [3] [4] . These drugs mainly interfere with HIV reverse transcriptase, but NRTIs can also be used by mitochondrial DNA (mtDNA) polymerase ␥ and, as a result, can interrupt replication of mtDNA. This may lead to depletion of mtDNA and defective production of proteins that are essential for oxidative phosphorylation, thereby decreasing the cellular energy production in terms of reduced levels of ATP [3, 5] .
Assessments of ART-associated mitochondrial toxicity have frequently used peripheral blood mononuclear cells (PBMCs) as the cellular source. However, depletion of mtDNA in PBMCs has been demonstrated even in HIVinfected, ART-naive patients [6 -8] . The possibility therefore exists that NRTIs may have a smaller impact than previously believed on mtDNA in circulating cells, compared with mtDNA in other tissues such as skeletal muscle, where the impact of NRTI on mtDNA is more overt [9] . Thus, the purpose of this study was to explore whether distinct mechanisms explain mtDNA loss in PBMCs between patients with and patients without exposure to ART. Our hypothesis was that, although NRTIs still might play a role in PBMCs from patients receiving ART, persistent immune activation may disturb mtDNA synthesis in those from ARTnaive patients. This chronic activation process is best linked to disease progression [10, 11] and possibly accounts for most of the chronic CD4 ϩ T cell loss in HIV infection [12] . However, lymphocyte turnover becomes enhanced not only among CD4 ϩ T cells (2-fold) and hyperactivated CD8 ϩ T cells (6-fold) [13] , but also among B lymphocytes [14] . We hypothesized that this immune activation might hamper mtDNA synthesis, and we therefore examined mtDNA in various PBMC subsets and correlated these results with the state of immune activation. mtDNA content was determined in purified CD4 ϩ and CD8 ϩ T cells, CD19 ϩ B cells, and CD14 ϩ monocytes from ART-naive and NRTI-exposed HIV-infected patients. We primarily used expression of the activation marker CD38 on CD8 ϩ T cells, which until recently was probably the best predictor of the rate of disease progression [10] . Recently, programmed cell death-1 (PD-1) was also found to play an important immune pathophysiological role through its involvement in reversible T cell exhaustion [15] . Our group recently described even better correlation to the rate of disease progression by combining data on PD-1 and CD38 expression [16] , and we therefore included both markers in our analysis.
SUBJECTS, MATERIALS, AND METHODS
Patients and control subjects. In a cross-sectional study, we consecutively enrolled 32 HIV-infected individuals: 17 had exposure to NRTIs (6 received didanosine, 7 received stavudine, and 8 received zidovudine), and 15 were ART naive. Ten NRTIexposed patients (59%) were currently receiving lamivudine. The additive duration of therapy was 44 months (range, 32-75 months) for didanosine, 59 months (range, 35-101 months) for stavudine, and 48 months (range, 20 -60 months) for zidovudine. Known mitochondrial or concomitant serious diseases, as well as current treatment with non-ART agents, were exclusion criteria. In addition, 14 age-matched, HIV-seronegative healthy control subjects were included in the analysis. We analyzed 12 additional HIV-infected, ART-naive patients who had been classified earlier as having either slow (6 patients) or rapid (6 patients) disease progression relative to the median rate of CD4 ϩ T loss (annual decrease, 45.7 cells/L) [16] . One patient in the group of rapid progressors was later discovered to have received zidovudine, lamivudine, and nevirapine 5 years earlier for 12 months, leaving 5 rapid progressors eligible for analysis. The protocol was approved by the regional ethics committee, and all participants gave their written informed consent. Quantification of cell surface markers by flow cytometry. Approximately 2 ϫ 10 5 cells in fresh EDTA-whole blood from 12 HIV-infected, ART-naive patients were stained with combinations of fluorescence-labeled monoclonal antibodies to human CD3, CD8, CD38, and PD-1 (BD). In addition, Quantibrite anti-CD38 with 1:1 PE labeling and Quantibrite PE beads (BD) was used to calculate the CD38 density in the T cell subsets (expressed as the median number of CD38 molecules per cell), according to the manufacturer's instructions [16] . Quantitative expression of PD-1 was determined by FITC-labeled monoclonal antibodies after careful standardization [16] .
The samples were analyzed by flow cytometry (FACS Calibur [BD]), and the data were further processed using Winlist analysis software (Verity SH).
Quantification of mtDNA and nuclear DNA. Total DNA was extracted from PBMCs, using the MagnNA Pure LC DNA isolation kit I (Roche Applied Science) according to the manufacturer's instructions. All DNA samples were stored at Ϫ70°C until real-time PCR analysis.
mtDNA copy number/cell was determined using the TaqMan PCR system (Applied Biosystems), as previously described [7] . Briefly, the quantification assay involves a multiplex analysis of mtDNA and nuclear DNA (nDNA) simultaneously, using primer and probe sequences as initially described by Andreasson et al. [17] . The mitochondrial target spanned over the genes for tRNA lysine and ATP synthase, and the nuclear target was the human retinoblastoma gene (RB1). Amplification and detection were performed in an ABI Prism 7000 sequence-detection system (Applied Biosystems). Standard curves from 10-fold serial dilutions of plasmid-cloned mitochondrion and RB1 PCR products with known concentrations were generated to estimate the mtDNA and nuclear DNA copy numbers in each sample [18] .
Statistical analysis. Data are presented as median values and interquartile ranges. Nonparametric tests were used throughout: the Mann-Whitney U test was used for group-wise comparison, Spearman rank correlation was used for analyzing associations between 2 continuous variables, and the Wilcoxon signed ranks test was used for comparing paired samples. All tests were 2-tailed. P values of Ͻ.05 were considered statistically significant. Data analysis was performed using SPSS, version 15.0 (SPSS).
RESULTS
mtDNA in PBMC subsets from NRTI-exposed patients, ARTnaive patients, and control subjects. We first analyzed mtDNA content after bead separation in PBMC subsets from subjects in a cross-sectional cohort (table 1). The purity of these subpopulations was assessed by FACS analysis and was Ͼ97% without detectable contaminating platelets, according to an automated cell counter. Distinct patterns of mtDNA concentrations were detected in the 2 HIV-infected groups. First, levels of mtDNA in CD8 ϩ T cells and CD19 ϩ B cells from HIV-infected, ART-naive patients were ϳ50% less than those in cells from control subjects (P ϭ .01 and P ϭ .004, respectively) (figure 1). In addition, HIV-infected, ART-naive patients had lower mtDNA levels in CD8 ϩ T cells than in CD4 ϩ T cells (P ϭ .008).
Second, in HIV-infected, NRTI-exposed patients, mtDNA levels in CD4 ϩ and CD8 ϩ T cells were similar and significantly less than those in T cells from control subjects (P ϭ .02 and P ϭ .01, respectively); however, mtDNA levels in CD19 ϩ B cells did not differ significantly between the 2 groups (figure 1). In HIV-infected, NRTI-exposed patients, a correlation was found between the mtDNA content in CD4 ϩ and CD8 ϩ T cells (r ϭ 0.83; P Ͻ .001). In both patient groups, mtDNA levels in CD14 ϩ monocytes were not significantly different from those for control subjects. It should further be noted that, for all groups, the mtDNA content in B cells was 2-4 times higher than those in both T cell subsets and in monocytes. We next investigated whether exposure to different NRTIs resulted in reduced mtDNA levels in PBMC subsets from HIV-infected, NRTI-exposed patients. The power of these analyses was hampered by the low number of patients in each subgroup. Nevertheless, patients currently receiving didanosine had the lowest mtDNA levels in both CD4 ϩ and CD8 ϩ T cells, compared with patients who were not receiving didanosine (P ϭ .002 and P ϭ .001, respectively) (figure 2). Moreover, increasing duration of didanosine exposure correlated negatively with mtDNA levels in CD4 ϩ T cells (r ϭ Ϫ0.48; P ϭ .05) and CD8 ϩ T cells (r ϭ Ϫ0.52; P ϭ .03), in keeping with the didanosine data presented above. In contrast, patients who were receiving other NRTIs, such as stavudine and zidovu- ϩ and CD8 ϩ T cell subsets from HIV-negative patients (HIV-), HIV-infected patients naive to antiretroviral therapy (HIVϩART-), and HIV-infected patients exposed to nucleoside reverse-transcriptase inhibitors that did not (NRTIϩddI-) or did (HIVϩddIϩ) include didanosine. P values were calculated by means of a 2-tailed Mann-Whitney U test. Squares, median values; whiskers, interquartile ranges. dine, had mtDNA levels similar to those in the NRTI-exposed group as a whole.
mtDNA depletion in ART-naive patients and its relationship to markers of persistent immune activation. ART-naive patients had reduced levels of mtDNA in CD8 ϩ T cells and CD19 ϩ B cells but not CD4 ϩ T cells, compared with control subjects. Because CD8 ϩ T cells and B lymphocytes are known to be particularly hyperstimulated in untreated chronic HIV infection [12, 14] , we quantified mtDNA in PBMC subsets from 11 HIV-infected, ART-naive patients who had been classified elsewhere as slow progressors (6 subjects) or rapid progressors (5 subjects) according to the rate of CD4 ϩ T cell loss [16] . Characteristics of this substudy cohort are presented in table 2. It should be noted that none of these patients were true long-term nonprogressors or "elite" controllers of HIV RNA levels. We first measured mtDNA levels in PBMC lymphocyte subsets and monocytes, which were obtained by cell sorting, and compared results between slow progressors and rapid progressors. Rapid progressors had lost significantly more mtDNA in CD4 ϩ T cells and CD19 ϩ B cells (P р .03) (figure 3). mtDNA levels in CD8 ϩ T cells were again reduced. In fact, mtDNA levels in rapid progressors were approximately two-thirds less than those in slow progressors, but the difference was not significant because of the low number of patients compared. Moreover, the possibility that similar mechanisms explain the mtDNA loss in both CD8 ϩ and CD4 ϩ T cells as well as B cells was supported by the fact that mtDNA levels in these cell subsets were strongly intercorrelated (r ϭ 0.74-0.93; P р .01). In contrast, mtDNA levels in CD14 ϩ monocytes were similar in both groups (figure 3), with no correlations with mtDNA levels in lymphocytes. Because the extent of immune activation in T cells during chronic HIV is a continuum, we next analyzed how mtDNA levels in PBMC subsets correlated with the following markers of activation: quantitative expression of CD38 on CD8 ϩ T cells, quantitative expression of CD38 on CD8
ϩ PD-1 ϩ T cells, and the difference in median CD38 fluorescence intensities (MFIs) between the CD8 ϩ PD-1 ϩ population and the CD38 MFI for all CD8 ϩ T cells. In T cells, mtDNA levels in both CD8 ϩ and CD4 ϩ subsets were negatively and strongly correlated with these activation markers (r ϭ Ϫ0.66 to Ϫ0.9; P р .03) (figure 4). In CD19 ϩ B cells, mtDNA levels likewise had a strong negative correlation with CD38 and PD-1 expression (r ϭ Ϫ0.68 to Ϫ0.84; NOTE. Data are no. of subjects or median value (interquartile range). The rate of disease progression was determined previously on the basis of the median rate of CD4 ϩ T loss (annual decrease, 45.7 cells/L) [16] . ART, antiretroviral therapy; HBV, hepatitis B virus; HCV, hepatitis C virus; NS, not significant; PD-1, programmed cell death-1.
a Calculated by the 2-tailed Fisher exact test or Mann-Whitney U test.
P Ͻ .02). Moreover, it should be noted that B lymphocytes were the only PBMC subset in which mtDNA levels correlated with disease progression in terms of the actual rate of CD4 ϩ T cell loss (r ϭ 0.66; P Ͻ .03). Again, mtDNA in these 3 lymphocyte populations were correlated with each other (r ϭ 0.74-0.93; P Ͻ .01), in keeping with the data from the cross-sectional cohort described above. It should be noted that mtDNA levels were also negatively correlated with HIV RNA levels in these lymphocyte subpopulations (r ϭ Ϫ0.87 to Ϫ0.74; P р .01). In contrast, data for the monocytes again differed from data for the lymphocytes: mtDNA levels in CD14 ϩ monocytes did not correlate with any of the immune activation markers or with mtDNA levels in the lymphocyte subpopulations; the only correlation was with patient age (r ϭ Ϫ0.73; P ϭ .01).
DISCUSSION
In this study, we hypothesized that distinct mechanisms cause mtDNA loss in HIV-infected patients who were exposed to NRTIs or naive to ART. To explore this, we isolated subsets of PBMCs with differential growth kinetics by magnetic beads and by cell sorting with a purity that was sufficiently high for this purpose. Moreover, we had no detectable contaminating platelets. Some natural killer (NK) cells might have contaminated the bead-separated CD8 ϩ T cells, but the low frequency of this cell type compared with the typically high CD8 ϩ T cell counts should not have significantly influenced our results, in keeping with similar mtDNA patterns of the CD8 ϩ T cells separated by sorting.
In this study, we did not assess mitochondrial function, which could possibly add important information about the impact of the mtDNA level on mitochondrial function. Instead, we compared mtDNA content in PBMC subsets rather than total PBMCs. We compared treated and untreated patients and, in the latter group, determined the relationship between mtDNA levels and markers of persistent immune activation. Although we included a relatively limited number of patients, significant differences between the groups were nevertheless found, suggesting that the mtDNA assay is capable of detecting changes that may be relevant.
First, in HIV-infected, ART-naive patients, mtDNA depletion was found in CD8 ϩ T cells as well as B cells. Because these lymphocyte subsets are known to be particularly hyperactivated in persons with chronic HIV infection [12, 14] , our data support the hypothesis that persistent activation and high cell turnover might have caused this mtDNA loss. One important mechanism for mtDNA loss may be the enhanced HIV-related apoptosis in these PBMC subsets, because mitochondria are key regulators of most apoptotic pathways [19] . In fact, the HIV-encoded proteins Vpr, Tat, Nef, and protease, as well as proinflammatory cytokines such as TNF-␣, IFN-␣, IFN-␥, IL-2, and IL-6, may all influence apoptosis [20, 21] . This is in agreement with a recent study in which mitochondrial dysfunction was associated with increased PBMC apoptosis in HIV progressors but not longterm nonprogressors [22] .
Depletion of mtDNA was less obvious in CD4 ϩ T cells; these lymphocytes are also activated in persons with chronic HIV infection, although to a lesser extent than in CD8 ϩ T cells and B cells [12, 16] . It should be noted, though, that mtDNA levels in CD4 ϩ T cells were lower in rapid progressors, compared with slow progressors. In fact, mtDNA depletion in CD4 ϩ T cells correlated highly with markers of persistent immune activation on CD8 ϩ T cells, in keeping with findings for the CD8 ϩ T cell subset and B cells. Our results are in agreement with findings of a recent study by Casula et al. [23] , who observed mtDNA loss in CD8 ϩ but not CD4 ϩ T cells in HIV-infected, ART-naive patients after seroconversion. Moreover, similar to our findings, mtDNA depletion in that study was also correlated with markers of immune activation (CD38 ϩ HLA-DR ϩ ) in a subset of 5 patients [23] . Second, one might question whether the mtDNA loss in ARTnaive patients could continue or perhaps even improve after initiation of ART, as a result of the reduced immune activation that is observed during effective ART [16] . It should be noted that the decrease in mtDNA levels in HIV-infected, NRTI-exposed patients differed from that in ART-naive patients and was found not only in CD8 ϩ T cells but also in CD4 ϩ T cells. In fact, this difference in mtDNA levels in the CD4 ϩ T cell subset could im- ply that quantification of mtDNA in CD4 ϩ T cells, rather than PBMCs, may better reflect NRTI-associated mitochondrial toxicity. Moreover, mtDNA loss was particularly significant in patients treated with didanosine, as might be expected because this drug uses kinases other than thymidine analogues for phosphorylation [5, 24] . In our study, mtDNA loss in cells of patients who received stavudine or zidovudine followed the same pattern as that observed in the NRTI-exposed group as a whole. This finding is in accordance with results of previous studies by us and others on mtDNA in PBMCs, all of which associated didanosine use with mtDNA loss in PBMCs [7, 25, 26] . Moreover, NRTI-treated patients without exposure to didanosine had higher levels of mtDNA in CD8 ϩ T cells, compared with ARTnaive patients. One might therefore speculate whether reduced immune activation after initiation of ART ameliorates mtDNA content in all patients except those treated with didanosine. In fact, increased levels of mtDNA after initiation of ART, including stavudine-containing regimens, have been reported by other groups [27, 28] . However, the extent to which the toxic effects of NRTI therapy accumulate after long-term treatment is unclear (e.g., what is the level of mtDNA depletion in precursor cells?).
On the other hand, reversibility of mtDNA depletion may be possible. We excluded 1 HIV-infected patient in the substudy cohort because the patient received zidovudine, lamivudine, and nevirapine 5 years earlier for 12 months. At the time of enrollment, this patient had mtDNA levels similar to the median values in all PBMC subsets from HIV-infected, ART-naive patients, including mtDNA levels in CD8 ϩ T cells that were 50% lower than those in CD4 ϩ T cells (data not shown). Taken together, these findings strongly suggest that the depletion of mtDNA in CD4 ϩ and CD8 ϩ T cells from NRTI-exposed patients is more likely to be associated with NRTI use. To our knowledge, this is the first study on mtDNA content in B lymphocytes from HIV-infected patients. We found that mtDNA levels in HIV-infected, ART-naive patients were ϳ50% less than those in B lymphocytes from uninfected control subjects. B lymphocytes are hyperactivated in patients with HIV infection who generally have hypergammaglobulinemia [29] . These data suggest similar mechanisms of mtDNA loss in CD8 ϩ T cells and B cells in untreated patients.
In conclusion, our data support the hypothesis that mechanisms of mtDNA depletion in ART-naive patients are distinct from those in NRTI-exposed patients and that persistent immune activation is closely linked to this depletion in the former group. Moreover, we found that mtDNA in B lymphocytes are particularly vulnerable to this phenomenon. Future analysis of mitochondrial toxicity in PBMCs from patients with chronic HIV infection may improve with studies on lymphocyte subsets rather than PBMCs.
